These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26726023)

  • 1. Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.
    Ahn JO; Li Q; Lee YH; Han SM; Hwang CY; Youn HY; Chung JY
    J Vet Sci; 2016 Sep; 17(3):431-3. PubMed ID: 26726023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
    Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
    Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
    Blanco Vela CI; Poo Ramírez JL
    Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention and treatment of hepatic encephalopathy].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.
    Soárez PC; Oliveira AC; Padovan J; Parise ER; Ferraz MB
    Arq Gastroenterol; 2009; 46(3):241-7. PubMed ID: 19918694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
    Buyeverov AO; Bogomolov PO; Mayev IV; Matsievich MV; Uvarova OV
    Ter Arkh; 2019 Mar; 91(2):52-58. PubMed ID: 31094172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
    Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S
    Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
    Mittal VV; Sharma BC; Sharma P; Sarin SK
    Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
    Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
    J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
    Abdo-Francis JM; Pérez-Hernández JL; Hinojosa-Ruiz A; Hernández-Vásquez JR
    Rev Gastroenterol Mex; 2010; 75(2):135-41. PubMed ID: 20615780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy.
    Ndraha S; Simadibrata M
    Acta Med Indones; 2010 Jul; 42(3):158-61. PubMed ID: 20724770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
    Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
    J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic.
    Butterworth RF
    Drugs; 2019 Feb; 79(Suppl 1):1-3. PubMed ID: 30706421
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
    Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
    Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Chen YP
    J Gastroenterol Hepatol; 2009 Jan; 24(1):9-14. PubMed ID: 18823442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
    Bai M; Yang Z; Qi X; Fan D; Han G
    J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
    Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S
    Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
    Kircheis G; Lüth S
    Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
    Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
    J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putative precipitating factors for hepatic encephalopathy in dogs: 118 cases (1991-2014).
    Lidbury JA; Ivanek R; Suchodolski JS; Steiner JM
    J Am Vet Med Assoc; 2015 Jul; 247(2):176-83. PubMed ID: 26133217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.